Möchten Sie immer auf dem neuesten Stand bleiben?

Oncolytics Biotech announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer.

It was an honor to attend the keynote address of Dr. Izpisúa whose scientific interests and vision for the future of humanity are world renowned

Launch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficient Well-established pharmaceutical technology...

All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a...

Eli Lilly's (NYSE:LLY) strong Phase 3 results for Retevmo places the oncology community in the spotlight

Oncolytics announced data demonstrating evidence of greater anti-tumor activity with pelareorep in combination with RAS inhibitor modalities.

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel...

NeOnc (NASDAQ:NTHI) is developing therapies and delivery technologies targeting aggressive brain cancers and CNS-related conditions, and could be part of t

SYDNEY, May 28, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces the successful outcome of its scheduled scientific advice meeting (written response) on Alzheimer’s...

This is the first NDA acceptance for BTK inhibitor orelabrutinib in autoimmune diseases. No BTK inhibitors have been approved in China for ITP.